검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Streptozocin |
Overview Company | Genentech, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Pancreatic Cancer |
Overview Indication | Pancreatic Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | , selective uptake via the glucose transporter type 2 transporter, and DNA-methylating properties provide a solid foundation for revisiting its therapeutic role and optimising its scheduling |
MoA Biomarker | biomarkers, such as O⁶-methylguanine-DNA methyltransferase deficiency and mismatch repair status, may |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | Pd |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | thrombocytopenia (decreased PLT count), leukocytosis (increased WBC count), and absolute neutrop |
Clinical Primary efficacy | ORR 8% |
Clinical ORR | 8% |
Clinical PFS | 71.4 |
Clinical OS | 61.7 |
Clinical Result source | ClinicalTrials.gov NCT02246127 |
Clinical Data Tier / Score | A · 38 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Streptozocin |
Overview Company | Genentech, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Pancreatic Cancer |
Overview Indication | Pancreatic Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | , selective uptake via the glucose transporter type 2 transporter, and DNA-methylating properties provide a solid foundation for revisiting its therapeutic role and optimising its scheduling |
MoA Biomarker | biomarkers, such as O⁶-methylguanine-DNA methyltransferase deficiency and mismatch repair status, may |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | Pd |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | thrombocytopenia (decreased PLT count), leukocytosis (increased WBC count), and absolute neutrop |
Clinical Primary efficacy | ORR 8% |
Clinical ORR | 8% |
Clinical PFS | 71.4 |
Clinical OS | 61.7 |
Clinical Result source | ClinicalTrials.gov NCT02246127 |
Clinical Data Tier / Score | A · 38 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교